Abstract. Wegener granulomatosis (WG) and microscopic polyangiitis (MP), diseases associated with antineutrophil cytoplasmic antibodies (ANCA), had an extremely poor prognosis before the introduction of cyclophosphamide and corticosteroids for their treatment. However, there is still reduced patient survival, and some studies have documented severe side effects of the immunosuppressants used. This 10-yr follow-up study assessed 117 consecutive patients with WG or MP with biopsy-confirmed renal involvement. The cumulative relative patient survival was lower: 0.664 for women and 0.648 for men. The causes of death (n ϭ 64) were in most cases registered as associated with the vasculitic disease. Analysis of possible predictive factors for patient survival by multiple Cox regression analysis revealed that a very high level of proteinase 3 (PR3)-ANCA measured by the capture ELISA method, a diagnosis of MP, and older age were factors predicting poorer patient survival. High levels of B-thrombocytes at time of diagnosis were associated with a better prognosis. For patients surviving the first year, remission-sustaining therapy with azathioprine for longer than 12 mo was associated with improved patient survival. Thirty-nine patients developed end-stage renal failure. Elevated serum creatinine at time of diagnosis and a very high level of PR3-ANCA by capture ELISA were factors predicting a higher risk for renal failure during follow-up. The epitope on PR3 assessed by capture ELISA needs to be further analyzed and explored: it seemed to implicate poorer patient and renal survival in WG or MP with renal involvement.
3 (PR3)-ANCA measured by the capture ELISA method, a diagnosis of MP, and older age were factors predicting poorer patient survival. High levels of B-thrombocytes at time of diagnosis were associated with a better prognosis. For patients surviving the first year, remission-sustaining therapy with azathioprine for longer than 12 mo was associated with improved patient survival. Thirty-nine patients developed end-stage renal failure. Elevated serum creatinine at time of diagnosis and a very high level of PR3-ANCA by capture ELISA were factors predicting a higher risk for renal failure during follow-up. The epitope on PR3 assessed by capture ELISA needs to be further analyzed and explored: it seemed to implicate poorer patient and renal survival in WG or MP with renal involvement.
Wegener granulomatosis (WG) and microscopic polyangiitis (MP) are diseases with a heterogeneous clinical presentation, although in most cases renal small vessel vasculitis will develop. Renal involvement is characterized by findings of a focal segmental necrotizing glomerulonephritis, crescent formation, and sparse immune deposition ("pauci-immune") (1) . Antineutrophil cytoplasmic autoantibodies (ANCA) are frequently found in sera from patients with WG and MP (2) , although their role in the pathogenesis of these diseases is still unclear. Autoantibodies to proteinase 3 (PR3), PR3-ANCA, are frequently detected in sera from patients with WG but could also be detected in 20% to 30% of sera from patients with MP, whereas autoantibodies to myeloperoxidase (MPO), i.e. MPO-ANCA, are more frequent in sera from patients with MP (58%) (3) . Further development of the ANCA assays are under way, and recently, we have presented data on a capture assay for detection of PR3-ANCA and found it to be more sensitive than conventional ELISA (4) .
The prognosis for patients with WG and MP was previously extremely poor before the use of immunosuppressive treatment, and if left untreated, patient survival was only 18% at 1 yr (5). However, after the introduction of therapy with cyclophosphamide and corticosteroids, patient survival improved to 80% at 5 to 8 yr of follow-up (6, 7) . In spite of this encouraging data, there has been no further improvement in patient survival, nor have decreased frequencies of relapses been observed. Relapses are frequent: about 50% of the patients have one or more relapse during 5-yr follow-up (7) (8) (9) , and side effects of the immunosuppression have been reported to be abundant, the most important of which are the risk of life-threatening sepsis and the development of malignant disease. Some reports have attempted to identify possible factors associated with poor patient survival. Some of these are older age, pulmonary involvement, or decreased renal function at baseline (10 -17).
In 1998, we published outcome data on 123 consecutive patients with WG or MP with renal involvement, reporting a relapse rate of 46% in a 5-yr follow-up and an 11-fold increased risk of developing urinary bladder cancer for patients treated with cyclophosphamide for a period longer than 12 mo. This cohort has now undergone another 5 yr of follow-up. The study presented here was aimed at investigating patient survival at 10 yr of follow-up, comparing the patient cohort with the general population of the same catchment area, and analyzing possible prognostic factors for patient outcome.
Materials and Methods
The cohort we studied comprised 123 consecutive patients with biopsy-confirmed renal involvement of WG or MP admitted to the Department of Nephrology, University Hospital of Lund, between 1971 and 1993; they were followed until the year 2000 or death. Six patients (four men and two women) were lost to follow-up. Two patients moved away, and for the remaining four patients, the medical records could not be retrieved, in spite of thorough research. The studied cohort thus comprised 117 patients, 75 men and 42 women. The date of the last visit in 1999 (in two patients in 1997, in another two in 1998, and in two in 2000) or the date of death was taken as the end of follow-up.
Clinical Diagnosis
As described in our previous report, subclassification into WG and MP was performed according to the Chapel Hill consensus (18) on the basis of findings at the time of referral to the department. For the diagnosis of WG, granulomatous inflammation, either proven histologically or strongly indicated by a noninvasive technique, was required. Clinical and laboratory data at baseline on the patients included are presented in Table 1 . Cancer cases were collected by the South Swedish Regional Tumor Registry.
Treatment Regimen
The policy was to institute daily oral therapy with cyclophosphamide, 2 mg/kg per day, and prednisolone 1 mg/kg per day. In cases presenting as rapidly progressive glomerulonephritis, adjunctive therapy with plasmapheresis or pulse methylprednisolone was added. After approximately 6 mo of remission, a switch was usually made from cyclophosphamide to azathioprine, 1 to 2 mg/kg per day orally. The prednisolone dosage was tapered to approximately 15 to 20 mg at 3 mo after initiation.
Remission was deemed complete if there was no evidence of active vasculitis with improvement of renal function and resolution of extrarenal manifestations of vasculitis. A partial remission was defined as nonprogressive disease with a tendency to remission-for example, stabilization of renal function or regression, although not complete resolution of pulmonary infiltrates.
Relapse was defined as the reappearance of activity of the vasculitic disease after achieving remission, with the occurrence of at least one of the following signs: rapid rise in serum creatinine (excluding any other cause of deterioration of renal function), new appearance of pulmonary infiltrates or hemoptysis without evidence of infection or malignancy, iritis, mononeuritis multiplex or vasculitis of the central nervous system, or active necrotizing vasculitis identified in any biopsy specimen.
Laboratory Investigation
Serum creatinine was measured by routine enzymatic methods with inter-and intra-assay coefficient of variation of Ͻ5% (reference interval, 60 to 115 mol/L). B-thrombocytes were analyzed with a Coulter or a Sysmex analyzer; inter-and intra-assay coefficient of variation with the Sysmex analyzer was 8% and 4%, respectively (reference interval, 140 to 400 ϫ 10 9 /L).
ANCA Analysis
Sera samples were drawn at the time of renal biopsy and stored at Ϫ20°C until analyzed. PR3-ANCA ELISA and MPO-ANCA ELISA microtiter plates coated with isolated human PR3 (19) and with human granulocyte MPO (20) , respectively, were obtained from Wieslab AB (Lund, Sweden) and the assays performed as described elsewhere (21) . The capture PR3-ANCA ELISA was performed as described previously (22) by using 4A3 as the monoclonal antibody coating the microtiter plates, allowing the capture of the purified PR3. 10 (8) PiZ gene determination for ␣ 1 antitrypsin analyses was carried out according to the method described by Wallmark et al. (23) and was performed at Wieslab AB. Information about cancer incidence in the studied cohort, whether before or developing after inclusion in the actual study, was obtained from the South Swedish Regional Tumor Registry.
Statistical Analyses
To calculate the cumulative relative survival (i.e., the observed survival rate of the patients compared with the survival rate, which is expected in an age-and gender-matched group of the general population similar to the group of patients at the beginning of the followup), we used the method described by Hakulinen and Abeywickrama (24) . The analysis was performed during 2002 at the South Swedish Regional Tumor Registry by Stata, version 7.0.
The causes of death were obtained from the South Swedish Regional Death Registry. Cox regression analysis was performed in a first step to evaluate potential predictive factors at baseline for reduced patient survival as well as renal survival. Because several prognostic factors were analyzed, and some of them may covariate, multiple Cox regression analysis was performed. Only the results obtained in the last step of the model, after removal of insignificant variables, were used. For the total patient survival analysis, 111 patients were included; data from 6 were excluded because of incomplete data. In the analysis of patients surviving the first year after diagnosis of WG or MP, data on 95 patients were included; 5 had to be excluded because of deficient data. Analysis for renal survival data included 109 patients.
The following variables were analyzed as possible predictive factors: age, gender, diagnosis (WG, MP), type of ANCA (PR3-, MPO-ANCA), capture PR3-ANCA level (Ͻ550 U, Ͼ550 U), PiZ gene, distribution of organ systems involved (subdivided into three groups: kidneys plus upper [excluding lower] respiratory tract; kidneys plus lower respiratory tract plus any upper respiratory tract; and kidneys plus other organ systems excluding the respiratory tract), serum creatinine, B-thrombocytes, and malignant disease before the diagnosis of WG or MP. In the analysis of patients surviving the first year, the duration of treatment with cyclophosphamide, azathioprine, and corticosteroids was included. The study was approved by the local ethics committee.
Results

Duration of Follow-up
The median duration of follow-up for the whole cohort was 92 mo (range, 0.1 to 336; Table 2 ) and extended to 153 mo (range, 39 to 336) for patients alive at the last follow-up.
Relapse
Relapses were noted in 66 (56%) of 117 patients during follow-up. Forty-three of these patients had one relapse, 10 had two, and the remaining 13 patients had three or more relapses.
Duration of Immunosuppressive Treatment
Data on duration of treatment with cyclophosphamide, azathioprine, and prednisolone are listed in Table 2 .
Patient Survival
At the end of follow-up, 53 of 117 patients were alive: 23 (55%) of the 42 women, and 30 (40%) of the 75 men. As shown in Figure 1 , 99 (85%) of 117 patients were alive at 1 yr of follow-up. The corresponding figures at 2 yr were 96 (82%), at 5 yr 86 (74%), and at 10 yr 44 (52%). To estimate patient survival according to age, the total cohort of patients was divided into quartiles. As shown in Table 3 , a decreasing proportion of survivors was recorded in the subgroups of elderly.
There was a statistically significant decreased patient survival compared with the general population, matched for age and gender in the same geographical region. Figure 2 shows the cumulative relative survival for men and women, respectively. Both men and women experienced decreased patient survival. The cumulative relative survival at 5 yr of follow-up was 0.838 (95% CI, 0.671 to 0.944) for women and 0.818 (95% CI, 0.694 to 0.910) for men. At 10 yr of follow-up, the cumulative relative survival was 0.664 (95% CI, 0.461 to 0.832) for women and 0.648 (95% CI, 0.500 to 0.799) for men. The numbers were too low to allow any statistical calculation at 15 yr of follow-up, although women seemed to live longer. As shown in Figure 2 , there was a striking drop in patient survival within the first year of follow-up: 16 (5 women and 11 men; 14%) of the 117 patients died.
Causes of Death
The most common diagnoses registered as the cause of death in the South Swedish Regional Death Registry were vasculitic disease, including glomerulonephritis and renal insufficiency in 21 cases, cardiovascular disease in 19, and cancer in 6. In at least four of the patients with cancer, there may have been a possible association with the immunosuppressive therapy, be- 16 (14) cause cancer in the urinary bladder (n ϭ 1), lymphoma (n ϭ 1), leukemia (n ϭ 1), and aplastic anemia (n ϭ 1) were registered. The remaining two patients who died as a result of malignancy had cancer in the gallbladder and kidneys, respectively. Pneumonia was registered in three patients, without any information about the causative agent, and meningitis in a single patient. In two patients, respiratory insufficiency was recorded as the cause of death, diabetes mellitus in two, and skeletal fracture or accidents in another three. Information was missing for seven patients because data on the causes of death after 1997 were not updated in the registry at the time of the present investigation.
Predictive Factors for Patient Survival
The results of the multiple Cox regression analyses testing for possible significant predictive factors for reduced patient survival are shown in Table 4 . The risk of dying was increased
The risk of dying was nearly twofold higher for patients with MP compared with those with WG (RR ϭ 1.917). A very high level of PR3-ANCA at time of diagnosis, Ͼ550 U, measured by the capture ELISA technique, yielded a significantly increased risk of death (RR ϭ 2.708; 95% CI, 1.538 to 4.768). High levels of B-thrombocytes at time of diagnosis were associated with a better prognosis. For patients with platelet counts Ͼ500 ϫ 10 9 , we found a RR of 0.029 (95% CI, 0.005 to 0.165), compared with those with levels in the lower range (Ͻ119 ϫ 10 9 ). Statistical analysis showed no significant correlation to gender, type of ANCA, heterozygosity for ␣ 1 antitrypsin deficiency (PiZ gene), distribution of organ system involvement at time of the diagnosis, or history or development of malignant disease. Regarding renal function at diagnosis, there was no correlation to patient survival when analyzed with multiple Cox regression analysis, as opposed to the result from the simple Cox regression analysis (P ϭ 0.010; data from the simple Cox regression not shown).
Predictive Factors for Patients Surviving the First Year of Follow-up
Analysis of possible predictive factors by multiple Cox regression analysis for patients surviving the first year after diagnosis revealed that older age and higher PR3-ANCA level (Ͼ550 U) by the capture ELISA method at the time of diagnosis were associated with poorer prognosis regarding patient survival. Treatment with azathioprine, used as remission-sustaining therapy, for more than 12 mo was associated with improved patient survival (RR ϭ 0.390; 95% CI, 0.202 to 0.752, Table 5 ). For gender, diagnosis, ANCA type, serum creatinine, PiZ gene, distribution of organ system involvement, B-platelet count, malignancy, duration of treatment with cyclophosphamide and prednisolone, and relapses, no statistically significant effect on patient survival was observed.
Renal Survival
At the end of follow-up, renal function was preserved in 78 patients, with serum creatinine (median) of 128 mol/L (range, 63 to 484). Thirty-nine patients (33%) had developed end-stage renal failure at the time of the last follow-up or death. The higher the serum creatinine at time of diagnosis, the poorer the renal survival. The RR for impaired renal function during follow-up was 1.349 for patients with slightly elevated serum creatinine the at time of diagnosis (120 to 199 mol/L) versus those with serum creatinine Ͻ120 mol/L, whereas the RR was 4.411 for those with serum creatinine Ͼ500 mol/L. Patients with very high levels of PR3-ANCA (Ͼ550 U) measured by capture ELISA showed a twofold risk of end-stage renal failure compared with those with lower levels (P ϭ 0.024; Table 6 ).
No statistical difference was found for renal survival when we considered gender, age, diagnosis, type of ANCA, heterozygosity for ␣ 1 antitrypsin deficiency (PiZ gene), or distribution of organ systems involved. High B-platelet count at the time of diagnosis seemed to reduce the risk for end-stage renal failure (RR, 0.053; 95% CI, 0.004 to 0.656). This finding did 
Incidence of Cancer
During the actual follow-up, a total of 16 cases of cancer were diagnosed, one more case (with cancer in the urinary bladder) than in our previous report in which the last follow-up was 1996. There were 13 cases of cancer in the male subgroup and 3 in the female subgroup. Thirteen patients who developed cancer after diagnosis of the vasculitis died during the follow-up period; notably, cancer was not registered as the cause of death in seven of these patients.
Discussion
Our findings of decreased patient survival in patients with WG or MP with renal involvement is in accordance with those of others (7, 12, 13, 16, (25) (26) (27) , although there are difficulties in comparing various studies because of inconsistencies such as great variations in duration of follow-up and the fact that several studies have exclusively included the diagnosis of WG but not MP. We could not detect a worse outcome for the subgroup of patients with WG compared with MP, which may be explained by the fact that in this material, the diagnosis of WG required the presence of a granulomatous disease, histologically verified or strongly suspected by x-ray. Thus, patients with sinus involvement, epistaxis, or hemoptysis, but without the above-mentioned criteria, received a diagnosis of MP. The dramatic decrease in patient survival during the first year has also been previously described by others (16, 17, 27) . However, to our knowledge, this is the first time that patient survival in ANCA-associated vasculitis with renal involvement has been presented as cumulative relative survival. By means of this approach, we have been able to more accurately evaluate patient survival for the studied disease, which was estimated to be 0.664 for women and 0.648 for men at 10 yr of follow-up. Not surprisingly, older age was a factor in impaired patient survival, as has been noted by others (13, 16, 25) .
The study presented here revealed that a very high PR3-ANCA level (Ͼ550 U) at baseline, measured by the capture assay technique, was associated with a statistically significant increased risk of decreased patient survival, in the short as well as in the long term. The risk of dying was 2.7 times higher for those with a high capture PR3-ANCA level. Our data could indicate that the epitope on PR3, recognized by the capture assay method, could be of importance in the pathogenesis of the disease, contrary to the epitope recognized by the direct ELISA.
We did not find elevated serum creatinine to be a prognostic factor for poor patient survival when we analyzed data by the multiple Cox regression analysis, as has been reported by others (11, 16, 28, 29) . A role for serum creatinine at baseline could not be excluded by this study, and interestingly, we found that in the simple Cox regression analysis, elevated serum creatinine seemed to be associated with poorer patient survival. A similar result was reported by Cohen and Clark (13), indicating a possible role for serum creatinine at baseline, although this finding did not reach statistical significance in their report either. Further analysis of our results revealed that there was a covariation of serum creatinine and age (i.e., older patients were often referred with a higher serum creatinine; data not shown). Twenty-one of the 67 patients older than 60 were admitted with a serum creatinine Ͼ500 mol/L, but only 8 of 50 patients younger than 60. Twenty-one of the 29 patients who were admitted with a serum creatinine above 500 mol/L died during the follow-up period. Because renal involvement of a vasculitic disease is, in many instances, silent, higher serum creatinine may reflect a more protracted form of the vasculitic disease, therefore implying a more serious outcome. It would of course have been better if the GFR had been measured by a clearance method, and not assessed as serum creatinine.
Regarding the distribution of organ involvement at baseline, there was no effect of types of organs involved-upper respiratory, lower and possible upper respiratory, or other organsand patient survival. This is in agreement with the findings of Slot et al. (17) and Mahr et al. (27) , but contrary to the reports by Hogan et al. (11) and Cohen and Clark (13) , in which decreased patient survival was recorded for patients presenting with pulmonary symptoms and signs.
Somewhat surprisingly, more than 12 mo of therapy with azathioprine resulted in improved patient survival (40%). Of course, one could argue against this finding, because the longer the patients were alive, the longer they would have the possibility of being exposed to azathioprine. But this remains the same for corticosteroids and cyclophosphamide, and no such association was found for either cyclophosphamide or corticosteroids. Cohen and Clark (13) found that therapy with azathioprine in patients with pauci-immune glomerulonephritis was one of the characteristics predicting favorable outcome of no death or no renal replacement therapy, although it did not reach statistical significance (P ϭ 0.0820). In this study, the B-platelet count at baseline seemed to be of importance both for patient and for renal survival. As stated earlier, there was no correlation between the levels of B-thrombocytes and B-leukocytes or B-hemoglobin, nor at the level of C-reactive protein.
At present, we have no explanation for this finding. Thrombocytosis is a well known feature of active inflammation in sera from patients with rheumatoid arthritis and has been proposed to be a result of a bone marrow stress response to shortened platelet survival with platelet sequestration (30) . One explanation of the lower levels of circulating thrombocytes could be production of more abundant aggregates of thrombocytes or Even if no association could be found between decreased patient survival and frequent relapses, the majority of the patients dying did so as a result of sequelae of the vasculitic disease or to cardiovascular disease. From our present data, we cannot tell how many of the cardiovascular deaths are a result of ANCA-associated vasculitis. Thus, long-term prospective multicenter trials are required to clarify this.
The present analyses did not reveal any effect on patient survival for the heterozygosity of the PiZ allele for ␣ 1 -antitrypsin, a finding in opposition to a previous report by Segelmark et al. (10) . The materials are not comparable, however, because our present cohort exclusively comprised patients referred to our university hospital. Thus, there could be a possibility that patients with a very aggressive course of the initial phase of the disease, with early death and possible carriage of the PiZ gene, may have been excluded. The frequency of the PiZ gene in sera from patients with MPO-ANCA-associated vasculitis was 13% (5 of 39) and seemed to be higher compared with the general population, in which 5% have been reported to carry the PiZ allele (31) . The prevalence of the PiZ allele was quite close to that obtained in sera from patients with PR3-ANCA of 18% (13 of 71), which is close to the 17% reported by Segelmark et al. (10) . To our knowledge, there has not yet been any report from a larger series of patients on the prevalence of the PiZ gene in patients with MPO-ANCAassociated vasculitis.
Regarding survival of renal function, our findings of elevated serum creatinine at referral and elevated levels of PR3-ANCA by the capture assay are in agreement with our previous study (22) . No such association was found for the levels of either PR3-or MPO-ANCA obtained by conventional ELISA. As far as we know, no such association has been found by others either.
As reported earlier, moderately elevated serum creatinine implies an increased risk for developing end-stage renal failure (25) . This finding stresses the importance of efforts to find the patients and start induction therapy as early as possible, before the impairment of renal function has begun.
One could argue that our present cohort is a selected cohort, and therefore one should not draw conclusions for the majority of patients with WG or MP. However, our present material seems to be similar to several others regarding distribution of age, gender, and laboratory measurements at the time of inclusion. Naturally, we can only extend our conclusions to patients with WG and MP with renal involvement at baseline. Another factor that may have had some influence on the present results is the fact that the patients were included over a rather long period of time, and we cannot rule out the possibility that there may have been some effect of time on the awareness of small vessel vasculitis and thus for the ease of diagnosis of WG and MP.
Our conclusion is that patients with an ANCA-associated small vessel vasculitis-that is, WG or MP-with renal involvement should be monitored early for PR3-ANCA level by the capture assay method, and patients with high levels of PR3-ANCA by this method should be treated and followed very carefully and intensively. We suggest that the epitope on PR3 assessed by the capture ELISA method needs to be further analyzed and explored because it seemed to imply poorer patient survival. Furthermore, at least 1 yr of remission therapy with azathioprine was found to be of benefit. The results from the ongoing study REMAIN from the European Vasculitis Study Group (32) may clarify more details on the optimal duration of remission therapy with azathioprine in patients with ANCA-associated vasculitis.
